Skip to content
OpenCapital
Get started

Lexicon Pharmaceuticals LXRX Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——
Cytokinetics logo
CytokineticsCYTK
——

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$986.12M+273%
Enterprise value$976.73M+219%
P/S14.2×+5.7×

Profitability

See full
Gross margin99.5%+1.5pp
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's increase (decrease) in accounts receivable?
Lexicon Pharmaceuticals (LXRX) reported increase (decrease) in accounts receivable of $9.4M in Q1 2026.
How has Lexicon Pharmaceuticals's increase (decrease) in accounts receivable changed year-over-year?
Lexicon Pharmaceuticals's increase (decrease) in accounts receivable increased by 1015.7% year-over-year, from -$1.03M to $9.4M.
What does increase (decrease) in accounts receivable mean?
This measures the net change in amounts owed to the company by customers for goods or services delivered on credit. An increase typically indicates rising sales or potential collection delays, while a decrease suggests effective cash collection. It is a critical component for assessing working capital efficiency and revenue quality.